Study flow diagram BB=blockers; HTN=hypertension; RCT=randomized controlled trial Bangalore S. et al. Am J Cardiol. 2007;100:1254-62.

Slides:

Advertisements

Similar presentations

11/2/ Implications of ASCOT Results for ALLHAT Conclusions ALLHAT.

Advertisements

Resistant hypertension increases patients’ cardiovascular risk 30% of all treated patients develop resistant hypertension [1-5]. Resistant hypertension.

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.

חזק בהגנה לבבית Valsartan in Heart Failure

NHANES III Prevalence of Hypertension* According to BMI

HYPERTENSION in ADPKD Sabine Karam M.D.. Introduction  ADPKD is the most common life-threatening single-gene disease  It affects over 12 million people.

Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.

The concept of Diabetes & CV risk: A lifetime risk challenge

Section 4: Managing progression of CKD. Glomerulosclerosis Reduction in number of functioning glomeruli Increased blood flow to remaining nephrons Intraglomerular.

1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.

Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

Randomized, double-blind, multicenter, controlled trial.

1 The Study of Trandolapril- verapamil And insulin Resistance STAR determined whether glycaemic control was maintained to a greater degree by an RAS inhibitor/non-DHP.

Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,

Sattar N, et al. Lancet 2010;375: Flow diagram of literature search to identify randomised placebo-controlled and standard care-controlled statin.

The TRial Of Preventing HYpertension (TROPHY) TROPHY.

Impact of Angiotensin Converting Enzyme Inhibitor versus Angiotensin Receptor Blocker on Development of Glucose Intolerance and New-onset Diabetes Mellitus.

Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.

CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

10/11/ Fasting Glucose Levels & Incident Diabetes Mellitus in Older Non-Diabetic Adults Randomized to Three Different Classes of Antihypertensive.

Federal Study of Adherence to Medications (FAME) Trial Presented at The American Heart Association Annual Scientific Session 2006 Presented by Dr. Allen.

ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:

7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.

Thiazide diuretics, Potassium, and the Development of Diabetes A Quantitative Review Hypertension2006_219.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Extension studies show sustained benefits with ACEI TreatmentRamiprilEnalaprilEnalaprilRamipril Follow-up15 mos10 yrs12 yrs7.2 yrs Characteristic Clinical.

Objective: To asses the efficacy of hydrochlorothiazide on 24-h blood pressure (BP) control.Methods: Review of all the randomized trials that assessed.

High-dose ARB monotherapy versus ARB/CCB combination on cardiovascular events in Japanese elderly high-risk hypertensive patients. The OSCAR trial Ogawa.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

Pre-ALLHAT Drug Use IMS Health NDTI, Year % of Treated Patients on Medication CCBs Beta Blockers Diuretics ACE Inhibitors.

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension Featured Article: Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra.

ACE inhibitors, ARBs and Statins in COPD: High- and Low-Risk Cohorts G. B. John Mancini, et al. J Am Coll Cardiol 2006;47:

1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH,

Wald DS, et al. Am J Med 2009;122: Details of the 42 Trials Included in the Meta-analysis - Part I Wald DS, et al. Am J Med 2009;122:

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease (HOPE-3 trial) R4. 박은지 / PF. 정혜문 Salim Yusuf, M.B., B.S., D.Phil.,

Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Hypertension J Am Coll Cardiol. 2006;48(8):

Study design: a randomized placebo- controlled crossover trial of 2 periods of 4 weeks Nicole A.J. van der Linde, et al. Hypertension 2006;47;

1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Usual Blood Pressure and Risk of New-Onset Diabetes:

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

Evidence based medicine Antihypertensive drugs in the elderly Group 1 and 6 -Heba Othman -Heba Sabry -Reem Ahmed -Dina Reda -Dalia El Magraby.

Blood Pressure and Lipid Trials: Rationale, Importance and Design

Vanguard Phase Results for the Blood Pressure Component

Flowchart of participants

Aliskiren and Valsartan for Antihypertensive Therapy Trial

Circ Cardiovasc Qual Outcomes

Mean BP from initial visit to four years

Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53

Description of studies for pooled analyses

Clinical Characteristics and Atheroma Burden of Subjects at Baseline Stratified According to Gender Nicholls SJ. et al. J Am Coll Cardiol 2007;49:

Baseline Characteristics, Blood Pressures, and Laboratory Values

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Baseline Lipid Parameters and Characteristics Among 3110 Men According to Quintiles of Total Cholesterol Ruben O. Halperin et al, Hypertension 2006;47;45-50.

Demographic and Clinical Characteristics (means ± SD or %) of Subjects in Different Office SBP and DBP Categories Mancia G et al Hypertension. 2005;45:1072.

Associations between type of MI and incident HF

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

Atrasentan reduces albuminuria in diabetic apoE KO mice.

End point Valsartan Valsartan+HCTZ p

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

Number of antihypertensive agents prescribed for known nephropaths in phases I and II (▪), with blood pressure recordings falling outside guidelines, compared.

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.

Fig. 3: Possible algorithm for controlling blood pressure in diabetic patients with microalbuminuria. [This algorithm is based on the opinions and practice.

Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.

Presentation transcript:

Study flow diagram BB=blockers; HTN=hypertension; RCT=randomized controlled trial Bangalore S. et al. Am J Cardiol. 2007;100:

Clinical trials comparing ß-blockers with placebo or diuretics Bangalore S. et al. Am J Cardiol. 2007;100:

Blood pressure response: ß-blockers versus placebo or diuretics

Bangalore S. et al. Am J Cardiol. 2007;100: Clinical trials comparing ß-blockers with nondiuretic antihypertensive agents

Bangalore S. et al. Am J Cardiol. 2007;100: Blood pressure response: ß-blockers versus nondiuretic antihypertensive agents

Bangalore S. et al. Am J Cardiol. 2007;100: Effect of ß-blockers on the risk for new-onset DM when compared to nondiuretic antihypertensive agents (CCBs, ACE inhibitors [ACEi], and ARBs)

Bangalore S. et al. Am J Cardiol. 2007;100: Effect of different ß-blocker types on the risk for new-onset DM compared with other agents

Bangalore S. et al. Am J Cardiol. 2007;100: Meta-regression analysis

Bangalore S. et al. Am J Cardiol. 2007;100: RR for new-onset DM (NODM) as a function of systolic blood pressure (SBP) difference between ß-blockers and nondiuretic antihypertensive agents

Bangalore S. et al. Am J Cardiol. 2007;100: RR for new-onset DM as a function of baseline fasting blood glucose levels

Bangalore S. et al. Am J Cardiol. 2007;100: RR for new-onset DM as a function of baseline BMI

Bangalore S. et al. Am J Cardiol. 2007;100: RR for new-onset DM as a function of length of follow-up

Bangalore S. et al. Am J Cardiol. 2007;100: ß-blockers for primary hypertension: pathogenesis for increased risk. BP=blood pressure SM=smooth muscle